Who are CROMOLYN SODIUM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bepreve, bepotastine besilate ophthalmic solution, Ketotifen/naphazoline, Alomide, Alocril, Intal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cromolyn-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CROMOLYN SODIUM — Competitive Intelligence Brief

CROMOLYN SODIUM (CROMOLYN SODIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mast cell stabilizer. Area: Oncology.

marketed Mast cell stabilizer Mast cells Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CROMOLYN SODIUM (CROMOLYN SODIUM).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CROMOLYN SODIUM TARGET	CROMOLYN SODIUM		marketed	Mast cell stabilizer	Mast cells	1982-01-01
Bepreve	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Ketotifen/naphazoline	Ketotifen/naphazoline	Bausch & Lomb Incorporated	phase 3	Mast cell stabilizer / antihistamine / decongestant combination	H1 receptor, mast cells, alpha-1 adrenergic receptor
Alomide	LODOXAMIDE	Novartis	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1993-01-01
Alocril	NEDOCROMIL	AbbVie	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1992-01-01
Intal	cromoglicic acid	Pfizer	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mast cell stabilizer class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CROMOLYN SODIUM — Competitive Intelligence Brief. https://druglandscape.com/ci/cromolyn-sodium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab